News BioMarin halts Voxzogo trials due to safety signal BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.
News Safety concerns prompt Ipsen to pull Tazverik from market Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.
News After phase 3 clean sweep, Roche plans oral BTK filing in MS Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?
R&D Sponsored Organoid neurotoxicity testing gains momentum Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.
News GLP-1 drugs linked to pancreatitis, gallbladder problems Users of weight-loss therapies based on GLP-1 agonists have been warned to be aware of a rare complication, pancreatitis, that can be severe.
News FDA seeks changes to GLP-1, flu shot labels The FDA has asked manufacturers of GLP-1 drugs used for weight loss to remove warnings of suicidal thinking, but added warnings to flu shots.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
